Raymond James Financial Inc. Takes Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Raymond James Financial Inc. bought a new position in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 54,453 shares of the company's stock, valued at approximately $1,026,000. Raymond James Financial Inc. owned 0.07% of Nurix Therapeutics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NRIX. Corebridge Financial Inc. lifted its stake in Nurix Therapeutics by 2.3% in the fourth quarter. Corebridge Financial Inc. now owns 34,907 shares of the company's stock worth $658,000 after acquiring an additional 770 shares during the period. US Bancorp DE lifted its position in shares of Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock worth $27,000 after purchasing an additional 842 shares during the period. Teacher Retirement System of Texas boosted its stake in shares of Nurix Therapeutics by 18.4% during the 4th quarter. Teacher Retirement System of Texas now owns 16,263 shares of the company's stock valued at $306,000 after purchasing an additional 2,532 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Nurix Therapeutics by 21.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 15,020 shares of the company's stock valued at $283,000 after buying an additional 2,632 shares during the period. Finally, SG Americas Securities LLC raised its stake in Nurix Therapeutics by 31.1% in the fourth quarter. SG Americas Securities LLC now owns 30,086 shares of the company's stock worth $567,000 after buying an additional 7,141 shares in the last quarter.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reaffirmed a "buy" rating and set a $36.00 price objective on shares of Nurix Therapeutics in a research report on Wednesday, April 2nd. JPMorgan Chase & Co. dropped their price target on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research report on Wednesday, January 29th. Royal Bank of Canada increased their price objective on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. Stifel Nicolaus reduced their target price on shares of Nurix Therapeutics from $36.00 to $35.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Finally, Leerink Partners started coverage on shares of Nurix Therapeutics in a research report on Monday, March 17th. They set a "market perform" rating and a $16.00 price target for the company. Three investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $30.44.

Insider Activity

In related news, CFO Houte Hans Van sold 2,438 shares of Nurix Therapeutics stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total value of $28,037.00. Following the completion of the sale, the chief financial officer now owns 39,922 shares of the company's stock, valued at $459,103. The trade was a 5.76 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Gwenn Hansen sold 3,377 shares of the company's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the sale, the insider now owns 61,516 shares of the company's stock, valued at approximately $707,434. This trade represents a 5.20 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 17,838 shares of company stock valued at $221,500 over the last three months. Insiders own 7.40% of the company's stock.

Nurix Therapeutics Trading Up 1.0 %

Nurix Therapeutics stock opened at $11.27 on Monday. The firm has a market cap of $859.18 million, a price-to-earnings ratio of -3.90 and a beta of 2.23. Nurix Therapeutics, Inc. has a 12 month low of $8.18 and a 12 month high of $29.56. The stock has a fifty day simple moving average of $12.03 and a two-hundred day simple moving average of $17.89.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its quarterly earnings data on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million during the quarter, compared to the consensus estimate of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same period last year, the company earned ($0.76) EPS. On average, equities research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.